<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

News

External stories on biodesix

Posts in: lung cancer

Clinical Lab Products: Predicting the Effectiveness of Anti-PD-L1 Therapy

In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians.

Clinical Lab Products: Overcoming Immune Blockade in Non-Small Cell Lung Cancer

Promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test.

The Pathologist: Has Tumor Profiling Caught Up to Cancer?

Dr. Skibo discusses how ddPCR-based liquid biopsy could become an indispensable method for doctors to categorize a patient’s disease.

The Pathologist: Battling Lung Cancer in the Tobacco Belt

Dr. Paul Walker describes how liquid biopsy testing helps battling lung cancer in the tobacco belt. The advantages of liquid biopsy for lung cancer.

Medical Laboratory Observer: Rapid Biomarker Testing for Improved Clinical Decision-making in Non-small Cell Lung Cancer

Dr. Skibo discusses how ddPCR-based liquid biopsy could be the solution to treatment delays due to receiving genetic information late.

Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial (Xconomy)

Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.

Putting Lung Cancer in the Bullseye (Breakthroughs)

Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.

Biodesix Feels the Buzz at BIO2012 (FierceBiomarkers)

Biodesix’s business model is based on two strands–clinical diagnostics and companion diagnostics; Tests based on the presence or absence of a biomarker.

A Test to Go With It (GenomeWeb)

Pharmaceutical companies are increasingly turning to companion diagnostic tests to determine whether a drug is suitable for a given patient.

Charting a Course for Progress Institute of Medicine Report Calls for Rigor and Standardization (The Burrill Report)

Biodesix's Jeffrey Bojar discusses Evolution of Translational Omics: Lessons Learned and the Path Forward and the rigorous framework it provides.

1 2 Last